EYPT

EyePoint Pharmaceuticals, Inc.

10.78 USD
-0.18 (-1.64%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

EyePoint Pharmaceuticals, Inc. stock is down -38.75% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 31.25% of the previous 15 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 May 19:17 19 Jul, 2024 10.00 CALL 100 1817
20 May 17:14 19 Jul, 2024 10.00 CALL 99 2071
20 May 17:15 19 Jul, 2024 10.00 CALL 388 2071
22 May 17:54 21 Jun, 2024 12.50 CALL 895 5232
22 May 17:55 21 Jun, 2024 12.50 CALL 4105 5232
22 May 18:54 17 Jan, 2025 17.50 PUT 105 7
28 May 13:37 19 Jul, 2024 10.00 CALL 317 2570
28 May 18:13 19 Jul, 2024 10.00 CALL 180 2570
29 May 17:51 19 Jul, 2024 10.00 CALL 209 3075
30 May 16:13 19 Jul, 2024 10.00 CALL 298 3075

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema. DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the. treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.

  • HC Wainwright & Co.
    Mon May 13, 06:56
    buy
    confirm
  • Baird
    Wed May 8, 07:01
    buy
    confirm
  • Chardan Capital
    Tue May 7, 08:48
    buy
    confirm
  • Mizuho
    Tue May 7, 07:04
    buy
    confirm